Skip to main content

Table 4 Percentage of the susceptibility of Pseudomonas aeruginosa strain to selected antibiotics .Data are presented as number and (%) of the susceptible strains in selected years

From: Pseudomonas aeruginosa device associated healthcare associated infections and its multidrug resistance at intensive care unit of University Hospital: polish, 8.5-year, prospective, single-centre study

 

Year

p-value

Antibiotics/Strains (n)

2011

2012

2013

2014

2015

2016

2017

2018

2019 (01–06)

20

18

7

13

12

5

14

10

9

Piperacillin/ tazobactam

8 (40)

9 (50)

3 (42.9)

7 (53.8)

6 (50)

3 (60)

13 (92.9)

5 (50)

2 (22.2)

p = 0.311

*p = 0.001

Ceftazidime

10 (50)

7 (38.9)

3 (42.9)

8 (61.5)

7 (58.3)

3 (60)

13 (92.9)

6 (60)

3 (33.3)

p = 0.335

*p = 0.0049

Cefepime

13 (65)

9 (50)

3 (42.9)

5 (38.5)

7 (58.3)

3 (60)

14 (100)

6 (60)

3 (33.3)

p = 0.225

*p = 0.0008

Imipenem

11 (55)

7 (38.9)

2 (28.6)

7 (53.8)

7 (58.3)

1 (20)

11 (78.6)

7 (70)

2 (22.2)

p = 0.129

*p = 0.0335

Meropenem

11 (55)

9 (50)

2 (28.6)

7 (53.5)

8 (66.7)

1 (20)

11 (78.6)

6 (60)

2 (22.2)

p = 0.1296

*p = 0.0335

Amikacin

11 (55)

13(2.7)

6 (85.7)

8 (61.5)

10 (83.3)

4 (80)

14 (100)

7 (70)

3 (33.3)

p = 0.427

*p = 0.008

Gentamicin

11 (55)

9 (50)

5 (71.4)

4 (30.8)

8 (66.7)

2 (40)

14 (100)

7 (70)

3 (33.3)

p = 0.427

*p = 0.0008

Ciprofloxacin

9 (45)

6 (33.3)

4 (57.1)

4 (30.8)

7 (58.3)

2 (40)

14 (100)

6 (60)

3 (33.3)

p = 0.4118

*p = 0.0008

Colistin

8 (100)

10 (100)

3 (100)

4 (100)

5 (100)

2 (100)

3 (100)

9 (100)

 
  1. Notes: p was calculated for the correlation of data 2011 vs. 2019; * p value for 2017 vs. 2019 Abbreviation: n number of P.aeruginosa strains